169 related articles for article (PubMed ID: 11899360)
1. Taxanes and capecitabine in combination: rationale and clinical results.
Maher JF; Villalona-Calero MA
Clin Breast Cancer; 2002 Jan; 2(4):287-93. PubMed ID: 11899360
[TBL] [Abstract][Full Text] [Related]
2. Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.
Verma S; Ilersich AL
Oncologist; 2003; 8(3):232-40. PubMed ID: 12773745
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
[TBL] [Abstract][Full Text] [Related]
4. Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies.
Nadella P; Shapiro C; Otterson GA; Hauger M; Erdal S; Kraut E; Clinton S; Shah M; Stanek M; Monk P; Villalona-Calero MA
J Clin Oncol; 2002 Jun; 20(11):2616-23. PubMed ID: 12039922
[TBL] [Abstract][Full Text] [Related]
5. Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer.
Puglisi F; Cardellino GG; Crivellari D; Di Loreto C; Magri MD; Minisini AM; Mansutti M; Andreetta C; Russo S; Lombardi D; Perin T; Damante G; Veronesi A
Ann Oncol; 2008 Sep; 19(9):1541-6. PubMed ID: 18441329
[TBL] [Abstract][Full Text] [Related]
6. Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models.
Fujimoto-Ouchi K; Tanaka Y; Tominaga T
Clin Cancer Res; 2001 Apr; 7(4):1079-86. PubMed ID: 11309360
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA
J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223
[TBL] [Abstract][Full Text] [Related]
8. Treatment for anthracycline-pretreated metastatic breast cancer.
O'Shaughnessy J; Twelves C; Aapro M
Oncologist; 2002; 7 Suppl 6():4-12. PubMed ID: 12454314
[TBL] [Abstract][Full Text] [Related]
9. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
O'Shaughnessy J; Miles D; Vukelja S; Moiseyenko V; Ayoub JP; Cervantes G; Fumoleau P; Jones S; Lui WY; Mauriac L; Twelves C; Van Hazel G; Verma S; Leonard R
J Clin Oncol; 2002 Jun; 20(12):2812-23. PubMed ID: 12065558
[TBL] [Abstract][Full Text] [Related]
10. The evolving role of capecitabine in breast cancer.
O'Shaughnessy JA
Clin Breast Cancer; 2003 Apr; 4 Suppl 1():S20-5. PubMed ID: 12756075
[TBL] [Abstract][Full Text] [Related]
11. A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Karachaliou N; Ziras N; Syrigos K; Tryfonidis K; Papadimitraki E; Kontopodis E; Bozionelou V; Kalykaki A; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2012 Jul; 70(1):169-76. PubMed ID: 22669571
[TBL] [Abstract][Full Text] [Related]
12. The role of capecitabine in first-line treatment for patients with metastatic breast cancer.
Gelmon K; Chan A; Harbeck N
Oncologist; 2006; 11 Suppl 1():42-51. PubMed ID: 16971739
[TBL] [Abstract][Full Text] [Related]
13. Future treatment options with capecitabine in solid tumours.
Wilke H
Eur J Cancer; 2002 Feb; 38 Suppl 2():21-5. PubMed ID: 11841932
[TBL] [Abstract][Full Text] [Related]
14. Capecitabine plus docetaxel combination chemotherapy for metastatic breast cancer.
Saeki T; Takashima S
Breast Cancer; 2004; 11(2):116-20. PubMed ID: 15550855
[TBL] [Abstract][Full Text] [Related]
15. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Fan Y; Xu B; Yuan P; Wang J; Ma F; Li Q; Zhang P; Li Q; Cai R
Chemotherapy; 2010; 56(4):340-7. PubMed ID: 20720418
[TBL] [Abstract][Full Text] [Related]
16. The search for enhanced therapeutic index in breast cancer: targeting the tumor and modulation of enzyme expression.
Budman DR
Cancer Invest; 2002; 20 Suppl 2():38-44. PubMed ID: 12442348
[No Abstract] [Full Text] [Related]
17. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients.
Blum JL; Dieras V; Lo Russo PM; Horton J; Rutman O; Buzdar A; Osterwalder B
Cancer; 2001 Oct; 92(7):1759-68. PubMed ID: 11745247
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
Schaller G; Fuchs I; Gonsch T; Weber J; Kleine-Tebbe A; Klare P; Hindenburg HJ; Lakner V; Hinke A; Bangemann N
J Clin Oncol; 2007 Aug; 25(22):3246-50. PubMed ID: 17577021
[TBL] [Abstract][Full Text] [Related]
19. What is the best schedule for administration of gemcitabine-taxane?
Colomer R
Cancer Treat Rev; 2005; 31 Suppl 4():S23-8. PubMed ID: 16360544
[TBL] [Abstract][Full Text] [Related]
20. Combination chemotherapy of the taxanes and antimetabolites: its use and limitations.
Smorenburg CH; Sparreboom A; Bontenbal M; Verweij J
Eur J Cancer; 2001 Dec; 37(18):2310-23. PubMed ID: 11720823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]